PALISADE BIO INC (PALI)
US6963892046 - Common Stock
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
– Live webcast with members of Palisade Bio management on Tuesday, April 16th at 12:00 PM ET Carlsbad, CA, April 11, 2024 (GLOBE NEWSWIRE) --...
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end ...
Let's take a look at the stocks that are in motion in today's session.
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Let's take a look at the stocks that are in motion in today's session.
Top movers in Monday's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Palisade Bio Announces 1-for-15 Reverse Stock Split
Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a...
PALI Stock Earnings: Palisade Bio Beats EPS for Q4 2023
PALI stock results show that Palisade Bio beat analyst estimates for earnings per share the fourth quarter of 2023.
PALI Stock Earnings: Palisade Bio Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Palisade Bio (NASDAQ:PALI) just reported results for the fourth quarter of 2023...
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused...
Palisade Bio names Donald Williams as chairman of the board (NASDAQ:PALI)
Palisade Bio appoints Donald Williams as chairman, causing shares to fall 2.4%.
Palisade Bio Provides Corporate Update and Reiterates Guidance
– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision – Advancement of...
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members
Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company...
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology,...
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company...
Why Is Palisade Bio (PALI) Stock Up 100% Today?
Palisade Bio is benefiting from a trio of positive news items, including encouraging preclinical data. Now PALI stock is blasting higher.
Palisade stock soars 150% on cancelled offering, potential reverse split (NASDAQ:PALI)
Palisade Bio (PALI) stock soared 150% Monday in the wake of news that it has cancelled a proposed offering and plans to conduct a reverse stock split instead. Read more here.
Palisade stock soars 150% on canceled offering, potential reverse split (NASDAQ:PALI)
Palisade Bio (PALI) stock soared 150% Monday in the wake of news that it has cancelled a proposed offering and plans to conduct a reverse stock split instead. Read more here.
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity...
Palisade Bio files to sell its shares (NASDAQ:PALI)
Palisade Bio (PALI) has filed a prospectus for the selling of its shares without disclosing the amount, clarifying it is not an offer to sell securities.
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
- Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s and Colitis...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday!
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook
– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral...
Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference
Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11,...
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and...